Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma

Oncogenic “driver” mutations are theoretically attractive targets for the immunotherapy of lymphoid cancers, yet the proportion that can be recognized by T cells remains poorly defined. To address this issue without any confounding effects of the patient's immune system, we assessed T cells fro...

Full description

Bibliographic Details
Main Authors: Julie S. Nielsen, Andrew R. Chang, Darin A. Wick, Colin G. Sedgwick, Zusheng Zong, Andrew J. Mungall, Spencer D. Martin, Natalie N. Kinloch, Susann Ott-Langer, Zabrina L. Brumme, Steven P. Treon, Joseph M. Connors, Randy D. Gascoyne, John R. Webb, Brian R. Berry, Ryan D. Morin, Nicol Macpherson, Brad H. Nelson
Format: Article
Language:English
Published: Taylor & Francis Group 2017-07-01
Series:OncoImmunology
Subjects:
driver mutation
ezh2
immunotherapy
lymphoma
myd88
neoantigen
next-generation sequencing
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1321184

Internet

http://dx.doi.org/10.1080/2162402X.2017.1321184

Similar Items